Denmark Pharmaceutical Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Denmark Pharmaceutical Market is segmented by ATC/Therapeutic Class, by Sector, and by Prescription Type

Market Snapshot

Denmark Pharmaceutical Market Overview
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 3.4 %
Denmark Pharmaceutical Market Major players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The pharmaceutical industry in Denmark is known worldwide for providing quality drugs and medical products. Furthermore, this country has a large base of pharma- and Biotech Industry, with several domestic companies researching and manufacturing pharmaceutical products. It has also been observed that turnover from the pharmaceutical industry increased in the past decade and grew steadily in the last four years. In Denmark, most of pharmaceutical spending is on prescription pharmaceuticals. Pharmacy stores are the main channel for pharmaceutical sales in the country, almost three-fourths of the turnover comes from prescription pharmaceuticals.

The largest pharmaceutical company in Denmark is Novo Nordisk, followed by two other large pharmaceutical companies headquartered in the country are H. Lundbeck, and Leo Pharma.

Scope of the Report

As per the scope of this report, pharmaceuticals are referred to as prescribed and non-prescription drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption for various illnesses with or without the doctor’s consent. The report also covers an in-depth analysis of qualitative and quantitative data.

By ATC/Therapeutic Class (Both Value and Volume)
Alimentary Tract and Metabolism
Blood and Blood Forming Organs
Cardiovascular System
Dermatological Drugs
Genitourinary System and Reproductive Hormones
Systemic Hormonal Preparations, excluding Reproductive Hormones and Insulin
Antiinfectives for Systemic Use
Antineoplastic and Immunomodulating Agents
Musculoskeletal System
Nervous System
Antiparasitic Products, Insecticides and Repellents
Respiratory System
Sensory Organs
Various ATC Structures
By Sector
Primary Sector
Hospital Sector
By Prescription Type
Prescription Drugs (Rx)
OTC Drugs

Report scope can be customized per your requirements. Click here.

Key Market Trends

Healthcare Expenditure Denmark

The healthcare expenditure in Denmark is expected to grow in the coming years. According to the data published by the OECD in 2015, the total current healthcare expenditure in Denmark was USD 4,674.5 million and this number is increased to USD 5,298.8 million in 2018. In Denmark, the framework which is controlling healthcare expenditure is outlined in a budget law, which sets budgets for regions and municipalities and specifies automatic sanctions if they are exceeded. Furthermore, the Inpatient pharmaceutical expenditure is controlled through national guidelines and clinical monitoring combined with collective purchasing. While the purchase of medicine takes place through tendering. The pharmaceutical companies report a monthly price list to the Danish Health Authority, and pharmacies are obliged to choose the cheapest alternative with the same active ingredient unless a specific drug is prescribed.

Furthermore, as per the estimates of the World Bank in Denmark, pharmaceutical spending accounted for 6.3% of the health spending in 2017. The rising healthcare expenditure is expected to increase the market for pharmaceuticals in the country.

Denmark Pharmaceutical Market Trends

Prescription Drugs (Rx) accounted for the Largest Share of the Total Pharmaceutical Sales in Denmark

In Denmark, the prescriptions are not covered under public health insurance. However, the national scheme does reimburse the partial costs of some medications. Furthermore, in Denmark, the direct-to-consumer advertising of prescription drugs is permitted under strict legislation. This is having a positive impact on the market as most off the pharmacists and end-users will be well aware of new or present medications available for the treatment of diseases. The prescription drug sales have increased as compared to previous years owing to the rising chronic disease, geriatric population, and rising healthcare expenditures.

Denmark Pharmaceutical Market Share

Competitive Landscape

The pharmaceutical industry is competitive and consists of several major players in Denmark having a major focus on research and development. Some of the major pharmaceutical companies in the country are Novo Nordisk A/S, H. Lundbeck A/S, Leo Pharma A/S, Orifarm Group A/S, ALK-Abelló A/S, Xellia ApS, Takeda Pharma A/S, Sandoz A/S, Ferring Pharmaceuticals A/S, and FUJIFILM Diosynth Biotechnologies

Table of Contents


    1. 1.1 Study Assumptions & Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

      1. 4.1.1 Healthcare Expenditure (Govt. Vs Private)

      2. 4.1.2 Pharmaceutical Imports and Exports

      3. 4.1.3 Epidemeology Data For key Diseases

      4. 4.1.4 Regulatory Landscape/Regulatory Bodies

      5. 4.1.5 Licensing and Market Authorization (For both Local Production and Imported Goods)

      6. 4.1.6 Pipeline Analysis

        1. By Phase

        2. By Sponsor

        3. By Disease

      7. 4.1.7 Statiscal Overview

        1. Number of Hospitals

        2. Employment in the Pharmaceutical Sector

        3. R&D Expenditure

      8. 4.1.8 Ease of Doing Business

    2. 4.2 Market Drivers

      1. 4.2.1 Collaboration between Private and Public Sector

      2. 4.2.2 Rising Funding for Research and Development

    3. 4.3 Market Restraints

      1. 4.3.1 High Tax Rates on Pharmaceutical Products

      2. 4.3.2 Price-cap Agreements

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By ATC/Therapeutic Class (Both Value and Volume)

      1. 5.1.1 Alimentary Tract and Metabolism

      2. 5.1.2 Blood and Blood Forming Organs

      3. 5.1.3 Cardiovascular System

      4. 5.1.4 Dermatological Drugs

      5. 5.1.5 Genitourinary System and Reproductive Hormones

      6. 5.1.6 Systemic Hormonal Preparations, excluding Reproductive Hormones and Insulin

      7. 5.1.7 Antiinfectives for Systemic Use

      8. 5.1.8 Antineoplastic and Immunomodulating Agents

      9. 5.1.9 Musculoskeletal System

      10. 5.1.10 Nervous System

      11. 5.1.11 Antiparasitic Products, Insecticides and Repellents

      12. 5.1.12 Respiratory System

      13. 5.1.13 Sensory Organs

      14. 5.1.14 Various ATC Structures

    2. 5.2 By Sector

      1. 5.2.1 Primary Sector

      2. 5.2.2 Hospital Sector

    3. 5.3 By Prescription Type

      1. 5.3.1 Prescription Drugs (Rx)

      2. 5.3.2 OTC Drugs


    1. 6.1 Novo Nordisk A/S

    2. 6.2 H. Lundbeck A/S

    3. 6.3 Leo Pharma A/S

    4. 6.4 Orifarm Group A/S

    5. 6.5 ALK-Abell A/S

    6. 6.6 Xellia ApS

    7. 6.7 Takeda Pharma A/S

    8. 6.8 Sandoz A/S

    9. 6.9 Ferring Pharmaceuticals A/S

    10. 6.10 FUJIFILM Diosynth Biotechnologies



**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Denmark Pharmaceutical Market market is studied from 2018 - 2026.

The Denmark Pharmaceutical Market is growing at a CAGR of 3.4% over the next 5 years.

Novo Nordisk A/S, Leo Pharma A/S, H. Lundbeck A/S, Orifarm Group A/S, ALK-Abelló Nordic A / S are the major companies operating in Denmark Pharmaceutical Market .

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!